Search

Your search keyword '"Dei‐Adomakoh, Yvonne"' showing total 48 results
Start Over Author "Dei‐Adomakoh, Yvonne"
48 results on '"Dei‐Adomakoh, Yvonne"'

3. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers

Author

Jiagge, Evelyn, Jin, Dexter X., Newberg, Justin Y., Perea-Chamblee, Tomin, Pekala, Kelly R., Fong, Christopher, Waters, Michele, Ma, David, Dei-Adomakoh, Yvonne, Erb, Gilles, Arora, Kanika S., Maund, Sophia L., Njiraini, Njoki, Ntekim, Atara, Kim, Susie, Bai, Xuechun, Thomas, Marlene, van Eeden, Ronwyn, Hegde, Priti, Jee, Justin, Chakravarty, Debyani, Schultz, Nikolaus, Berger, Michael F., Frampton, Garrett M., Sokol, Ethan S., and Carrot-Zhang, Jian

Published
2023
Full Text
View/download PDF

10. Sickle Cell Hemoglobin Genotypes Affect Malaria Parasite Growth and Correlate with Exosomal miR-451a and let-7i-5p Levels

Author

Oxendine Harp, Keri, primary, Bashi, Alaijah, additional, Botchway, Felix, additional, Addo-Gyan, Daniel, additional, Tetteh-Tsifoanya, Mark, additional, Lamptey, Amanda, additional, Djameh, Georgina, additional, Iqbal, Shareen A., additional, Lekpor, Cecilia, additional, Banerjee, Saswati, additional, Wilson, Michael D., additional, Dei-Adomakoh, Yvonne, additional, Adjei, Andrew A., additional, Stiles, Jonathan K., additional, and Driss, Adel, additional

Published
2023
Full Text
View/download PDF

11. Cervical precancer screening with HPV DNA testing and mobile colposcopy in women with sickle cell disease in Accra, Ghana.

Author

Dei-Adomakoh, Yvonne, Effah, Kofi, Tekpor, Ethel, Crabbe, Selina, Amuah, Joseph Emmanuel, Wormenor, Comfort Mawusi, Tay, Georgina, Asare, Eugenia Vicky, Kemawor, Seyram, Danyo, Stephen, Morkli, Esu Aku Catherine, Tibu, Faustina, Essel, Nana Owusu, and Akakpo, Patrick Kafui

Subjects
*SICKLE cell anemia, *MEDICAL screening, *MOBILE genetic elements, *COLPOSCOPY, *HUMAN papillomavirus, *CERVICAL intraepithelial neoplasia, *PARITY (Obstetrics), *HOME accidents
Abstract

Background: Worldwide, about 20-25 million people are affected by sickle cell disease (SCD), with 60% of patients living in sub-Saharan Africa. Despite recent therapeutic advancements resulting in improved life expectancy among SCD patients, the prevalence of high-risk human papillomavirus (hr-HPV) and cervical lesions have not been studied in women with SCD. We determined the prevalence of hr-HPV and cervical lesions among women with SCD and recommended strategies for reducing cervical cancer incidence in this cohort. Methods: Through the mPharma 10,000 Women Initiative, women with SCD attending routine visits at the Ghana Institute of Clinical Genetics SCD clinic were screened by trained nurses. Screening was performed via concurrent MA-6000 hr-HPV DNA testing and enhanced visual assessment (EVA) mobile colposcopy from mobileODT. Results: Among 168 participants screened (mean age, 43.0 years), the overall prevalence rates of hr-HPV infection and cervical lesions were 28.6% (95% CI, 21.7-35.4) and 3.6% (95% CI, 0.8-6.4), respectively. The hr-HPV prevalence rates stratified by haemoglobin genotype were 29.4% (95% CI, 19.7-39.1) and 28.6% (95% CI, 18.5-38.7) for genotypes SS and SC, respectively. None of the five women with the SF genotype tested hr-HPV positive, and the only patient with Sbthal genotype tested hr-HPV positive. Two women were EVA 'positive' but hr-HPV negative, whereas four were EVA positive and hr-HPV positive. Exploratory analysis revealed no significant associations between hr-HPV positivity and age, education level, marital status or parity. Conclusion: In the absence of a comprehensive national cervical screening programme aimed at including women with SCD as a special population, cervical cancer may increase in frequency among SCD patients. Thus, there is a need to build capacity and expand the scope of screening services for women with SCD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Adherence to hydroxyurea therapy and health-related quality of life in children with sickle cell anaemia at Korle Bu Teaching Hospital in Ghana

Author

Dwuma-Badu, Diana, Segbefia, Catherine I, Druye, Andrews A, and Dei-Adomakoh, Yvonne A

Subjects
hydroxyurea, adherence, quality of life, sickle cell anaemia, children, Ghana
Abstract

Background: Sickle cell anaemia (SCA) causes numerous acute and chronic complications, which can result in significant morbidity and mortality. Hydroxyurea (HU) therapy in individuals with SCA is associated with a reduction in disease severity.Objective: The study aimed to determine the relationship between adherence to HU therapy and health-related quality of life (HRQOL) scores in children with SCA (HbSS) at Korle Bu Teaching Hospital (KBTH) and identify any barriers to HU adherence.Methods: A cross-sectional descriptive study was conducted at the paediatric sickle cell clinic of the KBTH. One hundred and fifteen children aged 2 – 12 years with HbSS receiving HU therapy and their primary caregivers were enrolled on this study. Demographic and HU-related data were obtained from medical records and interviews with caregivers. The 8-item Morisky Medication Adherence Scale (MMAS-8©) and haematologic response based on mean corpuscular volume (MCV) were used to assess HU adherence. Caregivers and children aged 8 - 12 years also completed the Paediatric Quality of Life Inventory (PedsQLTM) SCD-module version 3.0. For children aged 5 – 7 years, the PedsQLTM SCD-module version 3.0 was administered by interview.Results: Seventy-nine (68.7%) of children had high adherence to HU therapy using the MMAS-8©. The mean PedsQLTM scores were 96.9 ± 6.0 and 96.3 ± 7.2 for the child (n = 91) and caregiver (n = 114), respectively. Children with high HU adherence had significantly higher PedsQLTM scores than those with low or moderate adherence. Neither child's current MCV nor mean change in MCV correlated with child or caregiver PedsQLTM scores. The main barrier to HU adherence identified by children aged  8 years was forgetfulness, while the cost of HU was the main barrier to adherence reported by caregivers.Conclusion: Children with SCA with high adherence to HU had the highest HRQOL scores using the PedsQLTM SCD-module version 3.0. Routine assessment of barriers to HU adherence can provide important information to help guide relevant interventions.

Published
2023

14. Evaluation of Treatment Patterns, Healthcare Resource Utilization and Cost of Illness for Sickle Cell Disease in Ghana: A Private Medical Insurance Claims Database Study

Author

Marfo, Kwaku, primary, Dei-Adomakoh, Yvonne, additional, Segbefia, Catherine, additional, Dwomoh, Duah, additional, Edgal, Adeline, additional, Ampah, Nancy, additional, Ramachandrachar, Badarinath, additional, Subramanyam, Kumaresan, additional, Natarajan, Ashok, additional, Egbujo, Olufolake, additional, and Ataga, Kenneth, additional

Published
2022
Full Text
View/download PDF

17. Additional file 1 of Rational design of an essential diagnostics network to support Universal Health Coverage: a modeling analysis

Author

Schroeder, Lee F., Dei-Adomakoh, Yvonne, DeStigter, Kristen, Idigbe, Emmanuel O., Flanigan, John, Ekpale, Priscilla Mawuli Awo, Adjei, Ernest, Roa, Lina, Wilson, Michael L., and Horton, Susan

Abstract

Additional file 1: Supplementary Figure S1. Cumulative Number of Diagnostics with Additional Diseases. Supplementary Table S1. Definitions of disease levels (uncomplicated vs complicated). Supplementary Table S2. Mapping of medicines to disease levels. Supplementary Table S3. Mapping of diagnostics to disease levels. Supplementary Table S4. Mapping of diagnostics to diagnostic formats. Supplementary Table S5. Infrastructural limitations of diagnostic formats. Supplementary Table S6. Model output of diagnostics by health facility tier. Supplementary Table S7. Minimum equipment investment and workforce skill needs, by health system tier.

Published
2022
Full Text
View/download PDF

18. Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low‐resource setting

Author

Asare, Eugenia Vicky, Olayemi, Edeghonghon, Boafor, Theodore, Dei‐Adomakoh, Yvonne, Mensah, Enoch, Ghansah, Harriet, Osei‐Bonsu, Yvonne, Crabbe, Selina, Musah, Latif, Hayfron‐Benjamin, Charles, Covert, Brittany, Kassim, Adetola A., James, Andra, Rodeghier, Mark, DeBaun, Michael R., and Oppong, Samuel A.

Published
2017
Full Text
View/download PDF

21. The BLOODSAFE program: Building the future of access to safe blood in Sub‐Saharan Africa.

Author

Delaney, Meghan, Telke, Susan, Zou, Shimian, Williams, Makeda J., Aridi, Jackline O., Rudd, Kristina E., Puyana, Juan Carlos, Kumar, Pratap, Appiah, Bernard, Dei‐Adomakoh, Yvonne, Asamoah‐Akuoko, Lucy, Olayemi, Edeghonghon, Singogo, Emmanuel, Hosseinipour, Mina C., M'baya, Bridon, Chipeta, Effie, Reilly, Cavan, Kamu, Robert, Aridi, Jackline, and Munoz‐Valencia, Alejandro

Abstract

Background: The supply of blood in many low‐ and middle‐income nations in Sub‐Saharan Africa (SSA) does not meet the patient care needs. Lack and delay of blood transfusion cause harm to patients and slow the rate of progress in other parts of the health system. Recognizing the power of implementation science, the BLOODSAFE Program was initiated which supports three SSA research study teams and one data coordinating center (DCC) with the goal to improve access to safe blood transfusion in SSA. Study Design and Methods: The study team in Ghana is focusing on studying and decreasing iron deficiency in blood donors and evaluating social engagement of blood donors through different approaches. The study team in Kenya is building a "vein to vein" workflow model to elucidate and devise strategies to overcome barriers to blood donation and improve infrastructural components of blood product production and use. The Malawi team is studying the infectious disease ramifications of blood donation as well as blood donor retention strategies aimed at blood donors who commence their donation career in secondary schools. Results and Discussion: Together the project teams and the DCC work as a consortium to support each other through a shared study protocol that will study donor motivations, outcomes, and adverse events across all three countries. The BLOODSAFE Program has the potential to lead to generalizable improvement approaches for increasing access to safe blood in SSA as well as mentoring and building the research capacity and careers of many investigators. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Multispectral Imaging for MicroChip Electrophoresis Enables Point-of-Care Newborn Hemoglobin Variant Screening

Author

An, Ran, primary, Huang, Yuning, additional, Rocheleau, Anne, additional, Avanaki, Alireza, additional, Thota, Priyaleela, additional, Man, Yuncheng, additional, Sekyonda, Zoe, additional, Segbefia, Catherine I., additional, Dei-Adomakoh, Yvonne, additional, Mensah, Enoch, additional, Odame, Isaac, additional, and Gurkan, Umut A., additional

Published
2021
Full Text
View/download PDF

23. Low FEV1 is associated with fetal death in pregnant women with sickle cell disease

Author

Hayfron‐Benjamin, Charles F., primary, Asare, Eugenia Vicky, additional, Boafor, Theodore, additional, Olayemi, Edeghonghon, additional, Dei‐Adomakoh, Yvonne, additional, Musah, Latif, additional, Mensah, Enoch, additional, Beyuo, Titus, additional, Kassim, Adetola A., additional, Rodeghier, Mark, additional, DeBaun, Michael R., additional, and Oppong, Samuel A., additional

Published
2021
Full Text
View/download PDF

28. Landscape of Oncology Clinical Trials in Africa

Author

Odedina, Folakemi T., primary, Shamley, Delva, additional, Okoye, Ifeoma, additional, Ezeani, Adaora, additional, Ndlovu, Ntokozo, additional, Dei-Adomakoh, Yvonne, additional, Meza, Kimberly, additional, Agaba, Ruth, additional, Fathi, Parisa, additional, and Askins, Nissa, additional

Published
2020
Full Text
View/download PDF

30. Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD

Author

Asare, Eugenia Vicky, primary, Olayemi, Edeghonghon, additional, Boafor, Theodore, additional, Dei‐Adomakoh, Yvonne, additional, Mensah Dip, Enoch, additional, Benjamin, Charles Hayfron, additional, Covert, Brittany, additional, Kassim, Adetola A., additional, James, Andra, additional, Rodeghier, Mark, additional, DeBaun, Michael R., additional, and Oppong, Samuel A., additional

Published
2019
Full Text
View/download PDF

35. Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting

Author

Oppong, Samuel A., primary, Asare, Eugenia V., additional, Olayemi, Edeghonghon, additional, Boafor, Theodore, additional, Dei-Adomakoh, Yvonne, additional, Swarry-Deen, Alim, additional, Mensah, Enoch, additional, Osei-Bonsu, Yvonne, additional, Crabbe, Selina, additional, Musah, Latif, additional, Hayfron-Benjamin, Charles, additional, Covert, Brittany, additional, Kassim, Adetola A., additional, James, Andra, additional, Rodeghier, Mark, additional, Audet, Carolyn, additional, and DeBaun, Michael R., additional

Published
2018
Full Text
View/download PDF

37. Bleomycin-induced pneumonitis in a young Ghanaian male with Hodgkin's Lymphoma.

Author

Dei-Adomakoh, Yvonne A., Afriyie-Mensah, Jane S., and Gbadamosi, Hafisatu

Subjects
*HODGKIN'S disease, *SUDDEN onset of disease, *PULMONARY fibrosis, *PNEUMONIA, *GERM cell tumors, *GHANAIANS
Abstract

We report a case of a young Ghanaian male who developed Bleomycin Induced Pneumonitis (BIP) after being treated for Hodgkin's Lymphoma. Pulmonary toxicity is the most feared complication of bleomycin therapy despite its effectiveness in achieving cure in patients with Hodgkin's lymphoma and germ cell tumors. BIP has a significant mortality rate if detected late and a high index of suspicion is required in all patients on bleomycin-based therapies with sudden onset of respiratory symptoms. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

39. A case series describing causes of death in pregnant women with sickle cell disease in a low-resource setting

Author

Asare, Eugenia Vicky, primary, Olayemi, Edeghonghon, additional, Boafor, Theodore, additional, Dei-Adomakoh, Yvonne, additional, Mensah, Enoch, additional, Osei-Bonsu, Yvonne, additional, Crabbe, Selina, additional, Musah, Latif, additional, Hayfron-Benjamin, Charles, additional, Covert-Greene, Brittany, additional, Kassim, Adetola A., additional, James, Andra, additional, Rodeghier, Mark, additional, DeBaun, Michael R., additional, and Oppong, Samuel A., additional

Published
2018
Full Text
View/download PDF

41. Presentation and survival of multiple myeloma patients in Ghana: a review of 169 cases.

Author

Acquah, Michael E., Hsing, Ann W., McGuire, Valerie, Wang, Sophia, Birmann, Brenda, and Dei-Adomakoh, Yvonne

Subjects
MULTIPLE myeloma, WEIGHT loss
Abstract

Background: Africans have an increased risk for multiple myeloma (MM) compared to other races. Reports from Africa are few and involve small cohorts, but suggest significant epidemiological and clinical differences from Caucasian patients. Objective: This report describes the clinic-pathological features of MM patients in Ghana at diagnosis, and the factors affecting their survival. Methods: A retrospective review of 169 MM cases diagnosed in a Ghanaian tertiary hospital from 2002-2016. Results: Median age was 58 years, with 29% ≤50 years. One-third presented >12 months after onset of symptoms, which included bone pain (96%), anaemia (67%), weight loss (55%) and fractures (44%). Myeloma-related tissue impairment included hypercalcaemia (36%), renal impairment (33%), severe anaemia (52%) and osteolytic lesions (76%); 51.3% of patients were diagnosed in ISS Stage III. Median survival was 33 months; 1-year and 5-year overall survival were 51.6% and 15.5%, respectively. Neither the age at diagnosis nor the duration of symptoms prior to diagnosis correlated with prognosis. Median survival improved with early ISS stage, haemoglobin >8g/dL, plasmacytosis <20%, and normal creatinine and calcium levels. Conclusion: Early onset and late stage presentation are common at diagnosis of MM patients in Ghana, but do not affect survival. Studies into genetic associations are recommended. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

42. Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low‐resource setting.

Author

Oppong, Samuel A., Asare, Eugenia V., Olayemi, Edeghonghon, Boafor, Theodore, Dei‐Adomakoh, Yvonne, Swarry‐Deen, Alim, Mensah, Enoch, Osei‐Bonsu, Yvonne, Crabbe, Selina, Musah, Latif, Hayfron‐Benjamin, Charles, Covert, Brittany, Kassim, Adetola A., James, Andra, Rodeghier, Mark, Audet, Carolyn, and DeBaun, Michael R.

Published
2019
Full Text
View/download PDF

43. Prospective Identification of Variables As Outcomes for Treatment (PIVOT): A Phase II Clinical Trial of Hydroxyurea for Children and Adults with HbSC Disease

Author

Segbefia, Catherine I., Smart, Luke R., Stuber, Susan E., Ekpale, Priscilla, Amissah-Arthur, Kwesi N., Dzefi-Tettey, Klenam, Mensah, Enoch, Lane, Adam C., Dwuma-Badu, Diana, Latham, Teresa S., Dei-Adomakoh, Yvonne, and Ware, Russell E.

Abstract

Introduction:HbSC is a common form of sickle cell disease especially prevalent in West Africa. Despite experiencing similar clinical events as those with sickle cell anemia (HbSS or HbSβ 0thalassemia), individuals with HbSC disease have received much less attention because disease complications occur less frequently and often manifest later in life. Retrospective reports suggest that hydroxyurea might benefit people living with HbSC disease, but rigorous prospective data are unavailable to describe potential treatment benefits, long-term safety, and appropriate study endpoints. We designed a Phase II clinical trial of hydroxyurea for children and adults with HbSC disease with the following aims: 1) to measure possible laboratory toxicities of hydroxyurea; 2) to assess the clinical effects of hydroxyurea on sickle-related clinical and laboratory parameters; and 3) to identify study endpoints that are suitable for a future definitive Phase III trial of hydroxyurea for HbSC disease.

Published
2023
Full Text
View/download PDF

44. Hematological Differences among Malaria Patients in Rural and Urban Ghana

Author

Iqbal, Shareen A., primary, Botchway, Felix, additional, Badu, Kingsley, additional, Wilson, Nana O., additional, Dei-Adomakoh, Yvonne, additional, Dickinson-Copeland, Carmen M., additional, Chinbuah, Helena, additional, Adjei, Andrew A., additional, Wilson, Michael, additional, Stiles, Jonathan K., additional, and Driss, Adel, additional

Published
2016
Full Text
View/download PDF

47. Comparison of Laboratory Data at Initial Diagnosis of Multiple Myeloma Between Black Africans, African Americans and White patients.

Author

Essiaw LA, Bolarinwa A, Tang H, Kudowor G, Shivaram S, Sharma N, Linden MA, Buadi FK, Rajkumar SV, Kumar S, Dei-Adomakoh Y, Cook JM, Baughn LB, and Paemka L

Abstract

Competing Interests: Disclosure S.K.K. served as a consultant for Celgene, Takeda, Amgen, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Takeda, Novartis, Amgen, AbbVie, Janssen, and Bristol-Myers Squibb. L.B.B. served as a consultant for Genentech.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results